In this issue:
ACR 2008 recommendations
Factors affecting referral/treatment with DMARDs
Clinical care of newly diagnosed RA in Scotland
Excellent outcomes with continued MTX monotherapy (SWEFOT)
Anti-TNF agent improves outcomes in MTX failure (SWEFOT)
Evidence-based recommendations for MTX use
Optimal MTX dosing in RA
Adalimumab dose escalation improves clinical responses in RA
Three papers on hydroxychloroquine and diabetes risk
A JAK inhibitor: well-tolerated and effective in RA
Treatment of RA with a Syk kinase inhibitor
Long term safety of rituximab
Two papers on safety of biologics after rituximab
Efficacy and safety of rituximab in SLE
Download PDF